logo
Share SHARE
FONT-SIZE Plus   Neg

Electromed Gets FDA Market Clearance For SmartVest SQL - Quick Facts

Electromed Inc. (ELMD), a global medical device company, said it has received notification from the U.S. Food and Drug Administration that its next generation SmartVest Airway Clearance System, the model SQL has been cleared to market.

"SQL solidifies Electromed's innovation leadership by offering a device that is smaller, quieter, and lighter than our previous versions," said Kathleen Skarvan, Chief Executive. He added, "We designed the SQL to stand apart from the competition with features that our patients and clinicians were asking for. They talked, and we listened."

The model SQL is an electrically powered precursor device designed to deliver high frequency chest wall oscillation to promote airway clearance, improve bronchial drainage and enhance mucus transport under the order of a physician's prescription.

The model SQL is expected to be available to the U.S. market within the next 60 days.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Rare commodities are worth more than good is a Chinese adage. And more so when it is in the sought-after drug space. Rare and ultra-rare diseases, also called orphan and ultra-orphan diseases, as the names imply, affect very small numbers of patients. So why the clamor? Shares of steel giant ArcelorMittal were losing around 4 percent in the early morning trading in Amsterdam after the company reported sharp decline in first-quarter EBITDA, a key earnings metric, as sales were weak with lower prices and production. Net loss, however, narrowed from last year. The company also confirmed its forecast for annual EBITDA, which is lower than last year. As the din settles down on a dismal quarter at one of the world's exciting tech company, it is time to sit back and take stock of what went wrong and will the wrong be righted in the near term?
comments powered by Disqus
Follow RTT